美国保险支付方政策与美国放射肿瘤学会(ASTRO)立体定向体部放疗(SBRT)模型政策之间的差异
研究比较了美国77家支付方及4家全国性福利管理机构在2015年后对SBRT「医学必要」适应症的政策变化,并与ASTRO模型政策进行对比。结果显示支付方对原发性肺癌(97%)、脊柱再照射(91%)等适应症认可比例较高,政策随时间与ASTRO模型政策趋于一致,全国性支付方覆盖比例高于区域性支付方,但区域层面仍需进一步对齐。
要点
- 支付方最常认可SBRT医学必要的适应症为原发性肺癌(97%)和脊柱再照射(91%)。
- 支付方政策随时间与ASTRO模型政策趋于一致。
- 全国性支付方和NBMs覆盖适应症的比例高于区域性支付方。
核心结论
- 尽管随时间有所改善,仍需更多工作使支付方政策与ASTRO的SBRT模型政策对齐,尤其是在区域层面。
研究设计与样本
- 从政策聚合器识别2015年有SBRT政策的77家支付方及4家全国性福利管理机构(NBMs),其中65家支付方和3家NBMs自2015年以来有公开更新。
- 对ASTRO模型政策中的每个适应症,计算认为SBRT医学必要的支付方比例。
- 使用Fisher精确检验比较2015年与当前、过去12个月内更新与更新频率较低的政策、以及当前全国性与区域性支付方之间的比例。
主要发现
- 支付方认为SBRT医学必要最常见的适应症为原发性肺癌(97%)、脊柱再照射(91%)、前列腺癌(68%)、原发性肝癌(66%)和放射抵抗组织学的脊柱转移瘤(66%)。
- 支付方政策随时间与ASTRO模型政策更加对齐。
- 全国性支付方和NBMs覆盖适应症的比例高于区域性支付方。
关键数值与推荐
- 原发性肺癌:97%的支付方认为SBRT医学必要。
- 脊柱再照射:91%的支付方认为SBRT医学必要。
- 前列腺癌:68%的支付方认为SBRT医学必要。
- 原发性肝癌:66%的支付方认为SBRT医学必要。
- 放射抵抗组织学的脊柱转移瘤:66%的支付方认为SBRT医学必要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Insurance payers in the United States vary in the indications for which they consider stereotactic body radiation therapy (SBRT) "medically necessary." We compared changes in policies after the last update to the American Society for Radiation Oncology's (ASTRO) SBRT model policy. METHODS AND MATERIALS: We identified 77 payers with SBRT policies in 2015 from a policy aggregator, as well as 4 national benefits managers (NBMs). Of these, 65 payers and 3 NBMs had publicly available updates since 2015. For each of the indications in ASTRO's model policy, we calculated the proportion of payers that considered SBRT medically necessary. We used Fisher's exact test to compare these proportions between 2015 and now, between policies updated in the past 12 months and those updated less often, and between national and regional payers currently. RESULTS: Payers consider SBRT medically necessary most often for primary lung cancer (97%), reirradiation to the spine (91%), prostate cancer (68%), primary liver cancer (66%), and spinal metastases with radioresistant histologies (66%). Policies have become more aligned with ASTRO's model policy over time. National payers and NBMs cover indications in higher proportions than regional payers. CONCLUSIONS: Although there have been improvements over time, more work is needed to align payer policies with ASTRO's model SBRT policy, especially at the regional level.
引用
- Roach MC, Thomas TO, Paravati AJ, et al. Differences in United States Insurance Payer Policies and American Society for Radiation Oncology's (ASTRO) Model Policy on Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol Biol Phys. 2019. PMID: 30677470. doi:10.1016/j.ijrobp.2019.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。